Want to see SE:GABA full AI Analyst Report?
Top Page
Gabather AB
(GABA)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr0.03
▼(-37.50% Downside)
Action:Reiterated
Date:09/17/26
The score is primarily weighed down by weak financial performance—no revenue, ongoing losses, and significant negative free cash flow—implying continued reliance on external financing despite having no debt. Technical signals are also bearish with the price below major moving averages and a negative MACD, while valuation is difficult to support given negative earnings and no dividend yield.
Positive Factors
Debt-Free Balance Sheet
The absence of reported debt reduces interest expense and refinancing exposure, giving Gabather greater financial flexibility than a similarly loss-making biotech with leverage. This supports continued research investment without debt-service obligations, although equity funding remains important.
Negative Factors
No Revenue or Commercial Base
Zero revenue means the company has not yet demonstrated commercial demand or an operating sales base to support its research activities. Until a candidate reaches commercialization or produces partnership income, future progress remains dependent on development milestones rather than recurring business revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
The absence of reported debt reduces interest expense and refinancing exposure, giving Gabather greater financial flexibility than a similarly loss-making biotech with leverage. This supports continued research investment without debt-service obligations, although equity funding remains important.
Read all positive factors
Gabather AB (GABA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr17.34M
Dividend YieldN/A
Average Volume (3M)2.33M
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue GrowthN/A
EPS Growth65.27%
CountrySE
Employees2
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding610,491,300
10 Day Avg. Volume1,469,667
30 Day Avg. Volume2,331,641
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-6.10
Price to Sales (P/S)0.00
P/FCF Ratio-0.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Gabather AB Business Overview & Revenue Model
Company Description
Gabather AB (publ) is dedicated to creating innovative pharmaceutical solutions for a range of central nervous system disorders. The company's focus includes developing medications for conditions such as psychotic illnesses, mood and anxiety disor...
Gabather AB Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
35
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -4.90M | -4.53M | -7.75M | 37.00K | -8.55M | -16.99M |
| Net Income | -5.00M | -4.65M | -7.75M | -9.44M | -8.54M | -17.00M |
Balance Sheet | ||||||
| Total Assets | 4.54M | 3.83M | 1.83M | 7.36M | 6.75M | 15.39M |
| Cash, Cash Equivalents and Short-Term Investments | 3.69M | 3.14M | 878.00K | 1.11M | 6.27M | 14.85M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 3.08M | 4.69M | 6.01M | 6.88M | 3.31M | 4.43M |
| Stockholders Equity | 1.46M | -863.00K | -4.17M | 486.00K | 3.44M | 10.96M |
Cash Flow | ||||||
| Free Cash Flow | -7.13M | -7.22M | -3.33M | -11.64M | -9.60M | -16.12M |
| Operating Cash Flow | -7.13M | -7.22M | -3.33M | -11.64M | -9.60M | -16.12M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 7.82M | 9.49M | 3.09M | 6.49M | 1.02M | 46.00K |
Gabather AB Technical Analysis
Negative
0.04
Price Trends
0.03
Negative
0.03
Negative
0.04
Negative
Market Momentum
>-0.01
Positive
43.89
Neutral
68.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GABA, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and above the 200-day MA of 0.04, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.89 is Neutral, neither overbought nor oversold. The STOCH value of 68.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:GABA.
Gabather AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | kr37.94B | 54.83 | 15.54% | ― | <0.01% | -6.75% | |
69 Neutral | kr29.04B | 270.59 | 5.18% | 0.67% | -46.09% | -90.13% | |
64 Neutral | kr1.39B | 7.39 | 29.71% | ― | 24.98% | -31.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr1.05B | 50.37 | 65.99% | ― | ― | ― | |
46 Neutral | kr440.01M | -1.42 | -136.72% | ― | -76.75% | -42.26% | |
42 Neutral | kr17.34M | -1.69 | -2479.40% | ― | ― | 65.27% |
* Healthcare Sector Average
SE:GABA
Gabather AB
0.03
>-0.01
-20.00%
SE:CAMX
Camurus AB
624.50
-57.00
-8.36%
SE:ORX
Orexo AB
12.50
-17.65
-58.54%
SE:ALZCUR
AlzeCure Pharma AB
7.52
5.19
222.89%
SE:BIOA.B
BioArctic AB Class B
322.00
34.31
11.92%
SE:SANION
Saniona AB
9.90
-1.50
-13.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.